Association of Body Mass Index and Age with Positive Receptors Expression and Metastasis Status Subtypes in Iraqi Women with Breast Cancer

Authors

  • Hamzah H. Kzar Lecturer, Veterinary Medicine collage, Al-Qasim Green University, Iraq Author
  • Moaed E. Al-Gazally Profesor, Collage of Medicine, Babylon university (works now at University of Al-Ameed), Iraq Author
  • Moshtak A. Wtwt profesor, Collage of Medicine, University of Babylon, Iraq Author

DOI:

https://doi.org/10.61841/0a8t2214

Keywords:

Breast cancer, Estrogen receptors alpha and beta (ERA, ERB), BMI, Metastasis status

Abstract

Background: Breast cancer (BC) is a heterogeneous disease witch produce from a number of genetic and epigenetic risks that lead to dysregulation of cell growth, circumvention of apoptosis, and development of the ability to invade the underlining tissue through the basement membrane. Aim: To assessment the association of BMI and age with positive receptors and metastasis status subtypes expression in Iraqi women of BC and determine the ERA and ERB and investigated the impact of those biomarkers alteration on the prognosis of patients with BC. Methods: This case-control study involved on 120 women with BC and same number as control group. Estimation of ERA and ERB were based on sandwich- ELISA. Results: The results examined that age and BMI of women with BC were significant associated with positive expression of ER and PR (p-value <0.05), but there were no association between those parameters and expression of Her-2 receptor subtype (pvalue >0.05). The results referred to a significant effects of age and BMI on expression of ER and PR in women with BC (OR=1.25 CI95%=0.49-3.51, OR=1.60 CI=0.61-4.16) (OR=1.4 CI95%=1.4-3.6, OR=1.83 CI95%=0.69-4.87), respectively. The results suggested the significant increase in incidence of IDC type of BC compare to ILC in women with (BMI ≥ 25) Conclusion: Assessment of ERA and ERB are useful in diagnosis and following up of women with BC in different ER, PR, ,Her-2, and in different histological grades. 

Downloads

Download data is not yet available.

References

1- PDQ Screening and Prevention Editorial Board. PDQ Cancer Information Summaries. National Cancer

Institute (US); Bethesda (MD) (2018). Breast Cancer Screening (PDQ®): Health Professional Version.

2- Doren A, Vecchiola A, Aguirre B, Villaseca P. Gynecological-endocrinological aspects in women carriers of

BRCA1/2 gene mutations. Climacteric;2018,21(6):529-535.

3- Van Keymeulen A, Lee M, Ousset M, Brohee S, Rorive S, Giraddi R et al . Reactivation of multipotency by

oncogenic PIK3CA induces breast tumour heterogeneity. Nature. 2015,525:119–23.

4- Wooster R and Weber B. Breast and onvarian cancer. N Engl J Med; 2013,348(23):2339.

5- Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature.

2012,490:61–70.

6- Siegel R, Miller K and Jemal A. Cancer Statistics. CA Cancer J Clin. ;2017, 67:7–30.

7- DeSantis C, Fedewa S, Goding Sauer A et al. Breast cancer statistics. Convergence of incidence rates

between black and white women. CA Cancer J Clin. 2016;66:31–42.

8- Sarab K et al. Risk factors of breast cancer among Iraqi women. J Contemp Med Sci : 2019,5, (3):149–153

9- Runnak A, Hemin A, Dana N, , Hazha A, Michae D. Breast cancer in Iraq is associated with a unimodally

distributed predominance of luminal type B over luminal type A surrogates from young to old age. BMC

women's health .2017,17:27.

10- Brewer H, Jones M, Schoemaker M et al. Family history and risk of breast cancer: an analysis

accounting for family structure. Breast Cancer Res Treat.2017 ;165:193–200.

11- Thakur P, Seam RK, Gupta MK, Gupta M, Sharma M, Fotedar V. Breast cancer risk factor

evaluation in a Western Himalayan state: A case–control study and comparison with the Western World.

South Asian J Cancer.2017, 6(3):106–109.

12- Runnak A, Hemin A, Dana N, et al. Breast cancer in Iraq is associated with a unimodally

distributed predominance of luminal type B over luminal type A surrogates from young to old age. BMC

Women Health.2017; 17: 27.

13- Al-Anbari, S. Correlation of the clinicopathological presentations in Iraqi breast cancer patients

with the finding of bio field breast cancer diagnostic system (BDS), HER-2 and Ki-67 immunohistochemical

expressions. Ph.D thesis, College of medicine, University of Baghdad, 2009.

14- Al-Sanati, M. PCR Study of BRCA1 BRCA2 in Correlation to Immunohistochemical Expression

of p53, Estrogen and Progesterone Receptors in Breast Cancer. Ph.D thesis, College of medicine, University

of Baghdad, 2009.

15- Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of

cancer: a systematic review and meta-analysis of prospective observational studies. Lancet.2008;371:569–

578.

16- Kang L, Weining Z, Zhiming D et al. Association between body mass index and breast cancer risk:

evidence based on a dose–response meta-analysis. Cancer Manag Res.2018; 10: 143–151.

17- Goldberg M et al. Early-Life Growth and Benign Breast Disease. Am J Epidemiol. 2019,

1;188(9):1646-1654.

18- Carol E et al. Breast Cancer Statistics, 2019. CA CANCER J CLIN.2019;69:438–451.

19- Macedo F, Ladeira K, Pinho F, Saraiva N, Bonito N, Pinto L, Goncalves F. Bone Metastases: An

Overview. Oncology Reviews. 2017,11 (1): 321.

20- Riethdorf S, Müller V, Zhang L, et al. Detection and HER2 Expression of Circulating Tumor Cells:

Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial. Clin

Cancer Res. 2010;16(9):2634–45.

21- Bahriye A, Sabine K, Volkmar M. et al. Comparison of the HER2, estrogen and progesterone

receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast

cancer patients. BMC Cancer.2016; 16: 522.

22- Linares A et al. Increased expression of the HDAC9 gene is associated with antiestrogen resistance

of breast cancers. Mol Oncol.2019;13(7):1534-1547.

23- Rothman MS, Carlson NE, Xu M, Wang C, Swerdloff R, Lee P, Goh VH, Ridgway EC, Wierman

ME. Reexamination of testosterone, dihydrotestosterone, estradiol and estrone levels across the menstrual

cycle and in postmenopausal women measured by liquid chromatography-tandem mass

spectrometry. Steroids.2011;76:177–82.

24- Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of

fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in

postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.J Clin

Oncol.2008; 26:1664.

25- Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R,

Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of

adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet.2011, 378(9793):771–84.

26- Yoko O and Hirotaka I. Clinical significance of estrogen receptor β in breast and prostate cancer from biological aspects. Cancer Sci.2015; 106(4): 337–343.

Downloads

Published

29.02.2020

How to Cite

H. Kzar, H., E. Al-Gazally, M., & A. Wtwt, M. (2020). Association of Body Mass Index and Age with Positive Receptors Expression and Metastasis Status Subtypes in Iraqi Women with Breast Cancer. International Journal of Psychosocial Rehabilitation, 24(1), 4917-4922. https://doi.org/10.61841/0a8t2214